Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation
Abstract. Secondary myelodysplastic syndrome (MDS) and acute leukemia (AL) are well-known complications of antineoplastic therapy. The incidence of these serious complications after autologous hematopoietic transplantation ranges from 1.1% to 24%. Prior chemotherapy is its most likely cause, but other variables related to these long-term complications are seriously discussed. There is evidence that priming of progenitor cells isolated from peripheral blood with chemotherapy is also related to a higher risk of secondary MDS/AL. Whether progenitor cells isolated from bone marrow or peripheral blood after mobilization only with cytokines are related to higher risk is a controversial issue. In this paper, we analyze the incidence and variables related to these complications in a series of 99 patients diagnosed with lymphoma or multiple myeloma who underwent autologous transplantation using hematopoietic progenitors isolated from peripheral blood mobilized with granulocyte colony-stimulating factor (G-CSF). The probability of MDS/AL in patients alive 5 years after transplant in our series is 8.58%, similar to that reported in other series using bone marrow grafts. The total dose of cyclophosphamide (p=0.099), the number of chemotherapy cycles (p=0.04) received before transplant, and the total dose of mononuclear cells infused at the time of transplant were the only variables associated with secondary MDS/AL. Autologous transplantation with progenitor cells isolated from peripheral blood after mobilization with cytokines has probability and risk factors for secondary MDS/AL development similar to bone marrow grafts when compared with other published series..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2001 |
---|---|
Erschienen: |
2001 |
Enthalten in: |
Zur Gesamtaufnahme - volume:81 |
---|---|
Enthalten in: |
Annals of hematology - 81(2001), 1 vom: 08. Dez., Seite 11-15 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Sevilla, J. [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Anmerkungen: |
© Springer-Verlag 2001 |
---|
doi: |
10.1007/s00277-001-0400-0 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2045493911 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | OLC2045493911 | ||
003 | DE-627 | ||
005 | 20230516154838.0 | ||
007 | tu | ||
008 | 200819s2001 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1007/s00277-001-0400-0 |2 doi | |
035 | |a (DE-627)OLC2045493911 | ||
035 | |a (DE-He213)s00277-001-0400-0-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
082 | 0 | 4 | |a 610 |q VZ |
100 | 1 | |a Sevilla, J. |e verfasserin |4 aut | |
245 | 1 | 0 | |a Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation |
264 | 1 | |c 2001 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © Springer-Verlag 2001 | ||
520 | |a Abstract. Secondary myelodysplastic syndrome (MDS) and acute leukemia (AL) are well-known complications of antineoplastic therapy. The incidence of these serious complications after autologous hematopoietic transplantation ranges from 1.1% to 24%. Prior chemotherapy is its most likely cause, but other variables related to these long-term complications are seriously discussed. There is evidence that priming of progenitor cells isolated from peripheral blood with chemotherapy is also related to a higher risk of secondary MDS/AL. Whether progenitor cells isolated from bone marrow or peripheral blood after mobilization only with cytokines are related to higher risk is a controversial issue. In this paper, we analyze the incidence and variables related to these complications in a series of 99 patients diagnosed with lymphoma or multiple myeloma who underwent autologous transplantation using hematopoietic progenitors isolated from peripheral blood mobilized with granulocyte colony-stimulating factor (G-CSF). The probability of MDS/AL in patients alive 5 years after transplant in our series is 8.58%, similar to that reported in other series using bone marrow grafts. The total dose of cyclophosphamide (p=0.099), the number of chemotherapy cycles (p=0.04) received before transplant, and the total dose of mononuclear cells infused at the time of transplant were the only variables associated with secondary MDS/AL. Autologous transplantation with progenitor cells isolated from peripheral blood after mobilization with cytokines has probability and risk factors for secondary MDS/AL development similar to bone marrow grafts when compared with other published series. | ||
700 | 1 | |a Rodríguez, A. |4 aut | |
700 | 1 | |a Hernández-Maraver, D. |4 aut | |
700 | 1 | |a de Bustos, J. |4 aut | |
700 | 1 | |a Aguado, M. |4 aut | |
700 | 1 | |a Ojeda, E. |4 aut | |
700 | 1 | |a Arrieta, R. |4 aut | |
700 | 1 | |a Hernández-Navarro, F. |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Annals of hematology |d Springer-Verlag, 1991 |g 81(2001), 1 vom: 08. Dez., Seite 11-15 |w (DE-627)130956759 |w (DE-600)1064950-5 |w (DE-576)025101188 |x 0939-5555 |7 nnns |
773 | 1 | 8 | |g volume:81 |g year:2001 |g number:1 |g day:08 |g month:12 |g pages:11-15 |
856 | 4 | 1 | |u https://doi.org/10.1007/s00277-001-0400-0 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OLC-DE-84 | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_21 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_101 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2018 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2339 | ||
912 | |a GBV_ILN_2424 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4082 | ||
912 | |a GBV_ILN_4219 | ||
912 | |a GBV_ILN_4277 | ||
912 | |a GBV_ILN_4302 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4314 | ||
951 | |a AR | ||
952 | |d 81 |j 2001 |e 1 |b 08 |c 12 |h 11-15 |